Mandated Payor Switching with Infliximab (IFX) Bioimilars
Authors:
Harry E. Sarles, MD, FACG – DHAT Research Institute, Richardson, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Sugar Land, TX
Thomas C. Hardin, PharmD – Healix Infusion Therapy, Sugar Land, TX